Using antidepressant drugs for treating menopausal symptoms
DOI:
https://doi.org/10.18597/rcog.237Keywords:
antidepressant drug, menopause, hot flushes, vasomotor symptoms, treatmentAbstract
Introduction: vasomotor symptoms are frequently reported during the peri and postmenopausal periods and drastically affect the quality of life of those women who suffer them. Estrogens continue being the treatment of choice for such symptoms; however, this type of treatment is contraindicated in some women, whilst other women simply refuse to use them. The present work was aimed at reviewing clinical studies which have evaluated antidepressant drugs’ effectiveness regarding the treatment of vasomotor symptoms.
Materials and methods: Medline / PubMed, EBSCO, and Ovid databases were reviewed. Articles published between 2002 and 2011 were included, as were randomized clinical assays, metaanalyses and systematic reviews which evaluated antidepressant drugs’ effectiveness in treating vasomotor symptoms.
Results: it was observed that antidepressants helped to alleviate vasomotor symptoms and had a favorable effect on neuropsychiatric symptoms related to the menopause, such as irritability, alterations in sleeping patterns and emotional ability. Studies regarding hot flushes’ physiopathology supported the hypothesis that antidepressants could be useful for treating them. Evidence regarding the group of antidepressant medicines suggested using sertraline, fluoxetine, citalopram and venlafaxine.
Conclusion: antidepressant drugs could be useful in treating menopause-related vasomotor symptoms; those having a noradrenergic and serotoninergic pharmacological profile should be considered.
Author Biographies
Mónica Flóres-Ramos
Jesús Rafael Aguilera-Pérez
References
Rödström K, Bengtsson C, Lissner L, et al. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002;9:156-61.
Blümel JE, Chedraui P, Baron G, Belzares E, Bencosme A, Calle A, et al. A large multinational study of vasomotor symptom prevalence, duration and impact on quality of life in middle-aged women. Menopause 2011 Mar 14. En prensa.
Horna A, Romero G, Horna M, Malacara JM, Pérez EL. El perfil sintomático en mujeres peri y posmenopáusicas. Ginec Obstet Mex 2006;74:312-6.
Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197-214.
Nelson HD. Postmenopausal estrogen for treatment of hot flashes. Clinical applications. JAMA 2004;291:1621-5.
Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million women study. Lancet 2003;362:419-27.
Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes, systematic review and meta-analysis. JAMA 2006;295:2057-71.
Joffe H, Soares CN, Cohen LS. Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatr Clin North Am 2003;26:563-80.
Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric 2007;10:23-6.
Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83.
Stearns V, Beebe K, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-34.
Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.
Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized, controlled, double-blind, crossover trial in a general population. Menopause 2006;13:546-8.
Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007;109:823-30.
Wu MF, Hilsenbeck SG, Tham yL, Kramer R, Elledge RM, Chang JC, et al. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat 2009;118:369-75.
Suvanto-Luukkonen E, Koivunen R, Sundströrm H, Bloigu R, Karjalainen E, Häiva-Mällinen L, Tapanainen JS. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo controlled, double blind study. Menopause 2005;12:18-26.
Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. Menopause 2007;14:223-9.
Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-83.
Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo LF, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri and postmenopausal women: impact on depression, vasomotor symptoms, sleep and quality of life. Menopause 2006;13:780-6.
Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen L, Joffe H, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-74.
Oishi A, Mochizuki Y, Otsu R, Inaba N. Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women. Biopsychosoc Med 2007;1:12.
Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22:94-7.
Loprinzi CL, Pisanski TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-81.
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000;356:2059-63.
Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147-52.
Walker EM, Rodríguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, et al. Acupunture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010;28:634-40.
Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S; Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebocontrolled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238.e1-238.e10.
Joffe H, Soares CN, Petrillo LF, Viguera AC, Somley B, Koch J, et al. Treatment of depression and menopause related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatr y 2007;68:943-50.
Tarim E, Bagis T, Kilicdag E, Erkanli S, Aslan E, Kuscu E. Moclobemide in the treatment of hot flashes in postmenopausal women. Adv Ther 2002;19:258-65.
Perez DG, Loprinzi CL, Barton DL, Pockaj BA, Sloan J, Novotny PJ, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004;2:50-6.
Pérez DG, Loprinzi CL, Sloan J, Novotny P, Barton D, Carpenter L, et al. Pilot evaluation of bupropion for the treatment of hot flashes. J Palliat Med 2006;9:631-7.
Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St John´s Wort for Climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247-55.
Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 2006;5:83-7.
Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: Focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011 Mar 14. En prensa.
Schnatz PF, Whitehurst SK, O'Sullivan DM. Sexual dysfunction, depression, and axiety among patients of an inner-city menopause clinic. J Womens Health (Larchmt) 2010;19:1843-9.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
